Confirmation of the Tumor Response by PET/CT for Lung Cancer Patients Treated with Alectinib: Our Clinical Experience

Journal
EC Pulmonology and Respiratory Medicine
Date Issued
2022-04-28
Author(s)
Abstract
Background: Anaplastic lymphoma kinase (ALK) rearrangement is identified in approximately 3-7% of all metastatic non-small cell
lung cancer (NSCLC) patients, and ALK tyrosine kinase inhibitors (ALKIs) have revolutionized the management of these patients.
Purpose: The aim of this study is to present treatment strategy with Alectinib and complete tumor response confirmed by PET/CT
for metastatic NSCLC patients at the University Clinic of Radiotherapy and Oncology in Skopje.
Material: The primary and point of our institutional study was assessed tumor response, duration of response DoR and CNS efficacy.
Tumor response evaluation we performed initial CT of the lung and abdomen or PET/CT (not able to perform for all patients in our
country), CT/MRI of the brain and then control previous images including if it possible PET/CT on 3 - 6 mounts, during follow-up
visits.
Results: We treated nine ALK positive patients with alectinib. We were presented complete tumor response in two of our patents
confirmed by PET/CT.
File(s)
Loading...
Thumbnail Image
Name

ECPRM-11-00935.pdf

Description
“Confirmation of the Tumor Response by PET/CT for Lung Cancer Patients Treated with Alectinib: Our Clinical Experience”
Size

1.1 MB

Format

Adobe PDF

Checksum

(MD5):048e7bb9ebd2f25a45b17f4fba95590f